Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03874286 · ClinicalTrials.gov registry record
The TOGETHER Project - Liver
A clinical trial of Liver Transplant Rejection, sponsored by Mayo Clinic.
- Completed
- Registry status
- 54
- Enrollment target
- 3
- Study locations
NCT03874286: Completed study of Liver Transplant Rejection, sponsored by Mayo Clinic.
NCT03874286 is a study of Liver Transplant Rejection that has completed, run by Mayo Clinic. The registered enrollment target is 54 participants, above the 37-participant average among 3 other Liver Transplant Rejection trials with a reported enrollment target (46% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03874286, a study of Liver Transplant Rejection, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
To validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.
Primary Outcome
The primary endpoint for this study is defined as obtaining the results of the RNAseq testing and to determine if an assay for rejection can be developed.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Liver Transplant
Study Locations (3)
Arizona
- Mayo Clinic - Phoenix
Florida
- Mayo Clinic - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2020-04-30 |
What the finished NCT03874286 record still lists
NCT03874286 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target, above the 37-participant average among 3 other Liver Transplant Rejection trials with a reported enrollment target (46% higher).
The record links to 1 condition, with Liver Transplant Rejection appearing as the primary indexed condition, and to 1 intervention - of which Liver Transplant is the first listed.
NCT03874286 reports a single indexed study location in Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03874286 about?
NCT03874286 is a clinical study titled "The TOGETHER Project - Liver". To validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.
What is the current status of trial NCT03874286?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2017-03-15. Estimated completion is 2020-04-30.
What conditions does trial NCT03874286 study?
This clinical trial studies the following conditions: Liver Transplant Rejection.
What interventions are being tested in trial NCT03874286?
The interventions under investigation include: Liver Transplant (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03874286?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03874286 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients
ACTIVE NOT RECRUITING
-
Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI